ArticleFrontiers in cardiovascular medicine2020
Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction.
Article in Frontiers in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 10 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- "In-Hospital Initiation of SGLT-2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis of Clinical, Decongestion, and Safety Outcomes".Cardiovascular drugs and therapy · 2026Pooled it
- The Impact of Early In-Hospital Use of SGLT2 Inhibitors on Outcomes in Patients With Acute Heart Failure: An Updated Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2026Pooled it
- The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Pooled it
- Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs.Frontiers in endocrinology · 2025Pooled it
- Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Pooled it
- Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE.BMC nephrology · 2023Guideline
- Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis.Global heart · 2023Pooled it
- Evaluating the Initiation of Sodium/Glucose Cotransporter 2 Inhibitors within 2 Weeks of an Acute Hospital Admission: A Systematic Review and Meta-Analysis of Nine Clinical Trials.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022Pooled it
- A review of the effect of SGLT2 inhibitors on clinical and glycemic outcomes in hospitalized patients: data from studies that included patients with diabetes.Hormones (Athens, Greece) · 2026Review
- Pilot study on the effects of dapagliflozin on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve disease.Veterinary and animal science · 2025Article
- SGLT2-is in Acute Heart Failure.Journal of clinical medicine · 2025Review
- Diuretics: a review of the pharmacology and effects on glucose homeostasis.Frontiers in pharmacology · 2025Review
- Effect of dapagliflozin on readmission and loop diuretics use in patients with acute heart failure: a retrospective propensity score-matched cohort study.BMC cardiovascular disorders · 2024Article
- Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Rehospitalisation rates of heart failure patients treated with SGLT2 inhibitors as an inpatient versus post-discharge.The British journal of cardiology · 2024Article
- Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use.Reviews in cardiovascular medicine · 2022Review
- Hypokalemia in Diabetes Mellitus Setting.Medicina (Kaunas, Lithuania) · 2022Review
- Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.European journal of heart failure · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.